Latest news with #YulingLuo
Korea Herald
4 days ago
- Health
- Korea Herald
Alamar Biosciences, Alzheimer's Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer's Disease.
Multi-center project will profile over 40,000 samples using ultra-sensitive NULISA™ technology. FREMONT, Calif., June 10, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, the Alzheimer's Disease Data Initiative and Gates Ventures today announced a strategic partnership with the goal to generate one of the largest proteomic datasets linked to clinical outcomes in Alzheimer's Disease (AD). This international project will profile over 40,000 plasma samples representing AD and related dementias using Alamar's ultra-sensitive NULISA™ technology, with the goal of accelerating biomarker discovery and driving new insights into the progression and treatment of AD. "This collaboration reflects our shared commitment to transform the landscape of Alzheimer's research through data, technology, and global partnerships," said Yuling Luo, PhD, Founder, Chairman and CEO of Alamar Biosciences. "By combining our NULISA platform with Alzheimer's Disease Data Initiative's infrastructure and Gates Venture's mission-driven investment, we aim to catalyze a new era of biomarker-driven discovery and therapeutic development." As part of the initiative, Alamar's NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 will be implemented at research centers in the United States, Sweden, United Kingdom, and India. These panels deliver unparalleled sensitivity and specificity, enabling the accurate measurement of hundreds of brain- and immune-related proteins from just a small volume of blood or cerebrospinal fluid. A key feature of the CNS panel is its unique ability to distinguish brain-derived phosphorylated tau from total phosphorylated tau in blood—a critical advancement for the development of community-based screening programs. The resulting proteomic data will be integrated with clinical and longitudinal outcome measures and shared with the global research community by leveraging the Global Neurodegeneration Proteomics Consortium 's (GNPC) secure data-sharing processes. "Understanding the biological underpinnings of Alzheimer's Disease is essential for developing effective treatments," said Niranjan Bose, Managing Director of Health & Life Sciences at Gates Ventures and interim Executive Director of the Alzheimer's Disease Data Initiative. "This initiative will provide a rich resource to researchers worldwide and help overcome long-standing barriers in early detection and stratified interventions." This initiative represents a major step forward in building a comprehensive, clinically annotated Alzheimer's plasma proteome atlas, with the potential to unlock new biomarkers for diagnosis, prognosis, and therapeutic response. This strategic collaboration complements the efforts of the GNPC, which has brought together top dementia researchers and datasets to collaborate and create one of the largest disease-specific proteomics datasets ever assembled. The project also emphasizes inclusivity by incorporating diverse cohorts from multiple geographic and ethnic populations. About the Alzheimer's Disease Data Initiative The Alzheimer's Disease Data Initiative is a coalition of leading academic, advocacy, government, industry, and philanthropy organizations that recognizes the need for dementia researchers to find easier ways to share data, analytical tools, and scientific findings. These partners are working together to accelerate progress towards new diagnostics, treatments, and cures for Alzheimer's disease and related dementias. Learn more about the Alzheimer's Disease Data Initiative at About Alamar Biosciences, Inc. Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA Platform along with the ARGO™ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit
Korea Herald
15-05-2025
- Health
- Korea Herald
Alamar Biosciences Expands NULISAseq™ CNS Disease Panel 120 with Groundbreaking Blood-Based Brain-Derived pTau Assays
First-of-its-kind panel includes brain-derived pTau217, pTau181, pTau231, and total tau assays to advance neurodegenerative disease research FREMONT, Calif., May 15, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced the expansion of its NULISAseq™ CNS Disease Panel 120 to include novel assays for brain-derived phosphorylated tau (pTau) proteins. The enhanced panel now features brain-derived pTau217, pTau181, pTau231, and total tau (tTau) protein measured directly from blood samples—delivering unprecedented sensitivity and specificity for the study of neurodegenerative diseases. Phosphorylated tau has emerged as a critical biomarker for early detection and monitoring of Alzheimer's disease and other tauopathies. The new additions to the CNS Disease 120 Panel are specifically designed to detect brain-derived forms of pTau, overcoming the limitations of current assays that cannot distinguish between peripheral and central tau species. This allows for the simultaneous measurement of two suites of multiple pTaus and tTau species, one specific for brain-derived and one combining brain- and peripheral tissue-derived Tau species. "Researchers have long sought a reliable, blood-based solution to track brain-derived tau pathology," said Dr. Yuling Luo, CEO, Founder and Chairman of Alamar Biosciences. "By integrating assays for pTau217, pTau181, pTau231, and total tau into our NULISAseq CNS Disease 120 Panel, we are enabling scientists to explore the full spectrum of tau pathology with exceptional sensitivity and throughput. This advancement is poised to accelerate biomarker-driven research and drug development in Alzheimer's Disease and related neurodegenerative disorders." "The ability to detect brain-derived pTau species directly from blood represents a transformative step in the early detection and monitoring of Alzheimer's Disease (AD) and related disorders," said Nicholas Ashton, Ph.D., Director of Neurodegenerative Biomarker Research at Banner Health. "Until now, we've been unable to differentiate between brain-derived and peripheral pTaus in a multiplexed manner. Recent evidence has underlined the importance of being able to detect brain-derived pTau for greater specificity for AD. Alamar's new CNS panel offers an unprecedented opportunity to further improve the diagnostic accuracy and clinical utilities of these biomarkers, which will dramatically impact patient care and clinical research." Alamar Biosciences remains committed to partnering with the neuroscience community to unlock biomarker insights that drive earlier diagnosis, patient stratification, and therapeutic monitoring. For more information about the NULISAseq CNS Disease Panel 120 and Alamar Biosciences' portfolio of proteomic solutions, visit About Alamar Biosciences, Inc. Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA Platform along with the ARGO™ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit
Yahoo
24-03-2025
- Health
- Yahoo
Alamar Biosciences Announces the Launch of the NULISAseq Mouse Panel 120
Providing the largest and most comprehensive, high sensitivity, protein biomarker analysis to advance pre-clinical research FREMONT, Calif., March 24, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce the launch of the NULISAseq Mouse Panel 120, an innovative biomarker profiling solution that provides the most comprehensive coverage of protein targets for expression analysis in mouse models. Designed to facilitate biomedical research and pre-clinical development studies, this cutting-edge panel analyzes 120 proteins covering key pathways in inflammation, neurodegeneration and immuno-oncology. "The NULISAseq Mouse Panel 120 encompasses an unparalleled selection of proteins essential for studying key biological pathways in pre-clinical models," said Yuling Luo, Ph.D., Founder, Chairman and CEO of Alamar Biosciences. "This robust panel is designed specifically for mouse models enabling researchers to gain valuable insights into disease mechanisms and therapeutic efficacy." With the broadest coverage of mouse protein targets, the NULISAseq Mouse Panel 120 is the only multiplex panel to include a specific focus on neurology content. This is crucial for researchers studying neurodegenerative diseases and the neurological effects of potential treatments. "I'm excited to incorporate the NULISAseq Mouse Panel 120 panel into my research studies." said Cheryl Wellington, Ph.D., Professor, Department of Pathology and Laboratory Medicine at University of British Columbia. "This state-of-the art panel provides me with the broadest view of neuro-physiology and has the potential to uncover new insights into the mechanisms of dementia and traumatic brain injury." Built on Alamar's novel multiplexing technology, the NULISAseq Mouse Panel 120 offers researchers a high-sensitivity, high-throughput solution to uncover complex biological mechanisms. The panel's attomolar (fg/ml) sensitivity and 10 logs of dynamic range allows for the detection of a wide range of proteins found in mouse plasma, even those that are low in abundance, such as p-tau217, from as little as 5 µl sample input. For more information, please visit About Alamar Biosciences, Inc. Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA™ Platform along with the ARGO™ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit View original content: SOURCE Alamar Biosciences, Inc.
